KaydedilenlerDerginizi ekleyin

Dergiler / Florence Nightingale journal of nursing (Online) / 2020 / Cilt: 28 - Sayı: 3

Henna Application in the Prevention of Capecitabine-Induced Hand-Foot Syndrome in Breast and Colorectal Cancer Patients

Gulbeyaz CAN
Pınar SAİP
Emel Emine KAYİKCİ
Fatma SEN
Sayfa
299–311
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Development time and severity of skin changes over time didnot differ significantly between the study and the control hand/foot.CONCLUSION: Further studies with a larger sample size are needed to conclude on the prophylactic effect of henna in the managementof the HFS

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:AIM: This study investigates the prophylactic effect of henna on the occurrence of hand-foot syndrome (HFS) in patients receivingcapecitabine for breast and colorectal cancer.METHOD: This experimental study was carried out between May 2014 and May 2015.
📊
Temel Bulgular & Veri:In this self-control experimental study, 52patients with breast and colorectal cancer were included on the first day of capecitabine treatment and had a minimum follow-upof 3 cycles.
💡
Sonuç & Katkı:Development time and severity of skin changes over time didnot differ significantly between the study and the control hand/foot.CONCLUSION: Further studies with a larger sample size are needed to conclude on the prophylactic effect of henna in the managementof the HFS
🔬Tür:Araştırma Makalesi
📍Kapsam:2014 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

AIM: This study investigates the prophylactic effect of henna on the occurrence of hand-foot syndrome (HFS) in patients receivingcapecitabine for breast and colorectal cancer.METHOD: This experimental study was carried out between May 2014 and May 2015. In this self-control experimental study, 52patients with breast and colorectal cancer were included on the first day of capecitabine treatment and had a minimum follow-upof 3 cycles. One hand/foot of each patient constituted the study hand/foot, whereas the others constituted the control. Henna wasadministered to the study hand/foot on the first day of treatment and application renewed weekly. Development of grade 1–3 toxicitywas set as the termination criterion for study.RESULTS: Painful skin changes such as rawness, intumescence and bulla formation, blocking the daily activities or self-care wereobserved in 26.9% of the patients in the 3rd or 4th cycles of treatment. Development time and severity of skin changes over time didnot differ significantly between the study and the control hand/foot.CONCLUSION: Further studies with a larger sample size are needed to conclude on the prophylactic effect of henna in the managementof the HFS

🔖

Bu Makaleye Atıf Yap

CAN, G., SAİP, P., KAYİKCİ, E. E., SEN, F. (2022). Henna Application in the Prevention of Capecitabine-Induced Hand-Foot Syndrome in Breast and Colorectal Cancer Patients. Florence Nightingale journal of nursing (Online), Cilt: 28 - Sayı: 3, 299–311. https://ajindex.com/articles/517369

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. American Cancer Society. (2016). Cancer treatment & survivorship facts & figures, 2016-2017. American Cancer Society; Atlanta. Abushullaih, S., Saad, E. D., Munsell, M., & Hoff, P. M. (2002). Incidence and severity of hand–foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience. Cancer İnvestigation, 20(1), 3-10. [Crossref] Ali, B. H., Bashir, A. K., & Tanira, M. O. (1995). Antiinflammatory, antipyretic, and analgesic effects of Lawsonia inermis L. (henna) in rats. Pharmacology, 51(6), 356-363. [Crossref] Baack, B. R., & Burgdorf, W. H. (1991). Chemotherapyinduced acral erythema. Journal of the American Academy of Dermatology, 24(3), 457-461. [Crossref] Bajetta, E., Procopio, G., Celio, L., Gattinoni, L., Della Torre, S., Mariani, L., Catena, L., Ricotta, R., Longarini, R., Zilembo, N., & Buzzoni, R. (2005). Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. Journal of Clinical Oncology, 23(10), 2155−2161. [Crossref] Blum, J. L., Dieras, V., Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001).
  2. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 92(7), 1759-1768.
  3. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England Journal of Medicine, 352(11), 1092-1102. [Crossref] Centers for Disease Control and Prevention. (2015). Global Cancer Statistics. Retrieved from: https://www.cdc.gov/ cancer/international/statistics.htm. Chen, M., Zhang, L., Wang, Q., Shen, J. (2013). Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: A systematic review. PLoS ONE, 8(8), e72245. [Crossref] Chidharla, A., Kasi, A. (2019). Cancer, chemotherapy acral erythema (palmar-plantar erythrodysesthesia, palmoplantar erythrodysesthesia, hand-foot syndrome. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Chin, S. F., Chen, N & Oza, A. (2001). Use of ‘Bag Balm’ as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents. Proceedings of The American Society of Clinical Oncology, 20, 409a. Common Terminology Criteria for Adverse Events (CTCAE). (2010). Retrieved from: h